Amwell vs HeartFlow
Amwell reported revenue of $249 million in fiscal 2025, 1.4 times HeartFlow's $176 million in fiscal 2025. Amwell's revenue fell 2.0% in its latest year, and HeartFlow's grew 39.9%. Amwell had an operating margin of -42.2%, against -36.4% at HeartFlow. Free cash flow was −$66 million at Amwell and −$59 million at HeartFlow.
Side by side
| Amwell | HeartFlow | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $249M | $176M |
| Revenue growth | −2.0% | 39.9% |
| Revenue growth a year, last 5 years | 0.3% | — |
| Gross margin | — | 76.8% |
| Operating margin | −42.2% | −36.4% |
| Net margin | −38.4% | −66.3% |
| Free cash flow | −$66M | −$59M |
| Free cash flow margin | −26.5% | −33.5% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 7.0% | 587.1% |
| Last close | $10.69 | $44.63 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $4,938, sold $792,528 | bought $1.1 million, sold $142.3 million |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
AmwellHeartFlow
Operating margin
Percent of revenue
AmwellHeartFlow
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
AmwellHeartFlow